fda decision on tirzepatide Allows Compounded During Shortage Review GLP-1 Drugs: FDA “Re-Confirms” Decision

Nutrients 16(6):802

Showing the decrease in that calculated risk as patients lab results improve with treatment can reinforce GLP-1 drugs positive health impact and demonstrate their value in preventive care

53 Treatment lengths ranged from 1 to 7 months, with a mean duration of seven weeks to four months until visible clinical improvement was noted

For patients with thyroid disease, semaglutide has a longer safety track record in this population compared to tirzepatide, which entered clinical use more recently

Once the first dose is drawn from a vial or the first injection given from a pen, the in-use period begins